Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Inclusion Criteria: * Abdominal pain/discomfort with onset prior to hospitalization * Evidence of a systemic inflammatory response * Physical findings consistent with intra-abdominal infection (IAI) * Clinical diagnosis of community-acquired IAI requiring urgent surgical or percutaneous intervention and not expected to require antibacterial therapy for longer than 14 days * Body mass index (BMI) of ≤ 30 kilograms per square meter (kg/m\^2) * Able to provide informed consent. If the participant is unable to provide informed consent, the participant's legally acceptable representative may provide written consent in accordance with institutional guidelines * If female, not pregnant or nursing or, if of child-bearing potential either: will commit to use at least two medically accepted, effective methods of birth control (for example, condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring) during study drug dosing and for 90 days following last study drug dose or practicing sexual abstinence Exclusion Criteria: * Symptoms related to diagnosis of complicated appendicitis (if current diagnosis) for \< 24 hours prior to current hospitalization * Previously hospitalized or admitted to a healthcare facility within the last 6 months * Managed by Staged Abdominal Repair or other open abdomen technique * Known at study entry to have an IAI caused by a pathogen(s) resistant to both study drug antibiotics * Acute Physiology and Chronic Health Evaluation (APACHE) II score \> 25 * Unlikely to survive the 6-8 week study period * Any rapidly-progressing disease or immediately life-threatening illness, including acute hepatic failure, respiratory failure and septic shock * Requirement for vasopressors at therapeutic dosages * Renal failure * Presence or possible signs of hepatic disease * Hematocrit \< 25% or hemoglobin \< 8 grams per deciliter (g/dL) * Neutropenia with absolute neutrophil count \< 1000 cells per cubic millimeter (mm\^3) * Platelet count \< 50,000/mm3 * Abnormal coagulation tests or participant on anticoagulants * Immunocompromised condition, including known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS), organ (bone marrow) transplant recipients, and hematological malignancy. Immunosuppressive therapy, including use of high-dose corticosteroids (for example, \> 40 milligrams \[mg\] prednisone or equivalent per day for greater than 2 weeks) * History of hypersensitivity reactions to tetracyclines or carbapenems * Participation in any investigational drug or device study within 30 days prior to study entry * Known or suspected central nervous system (CNS) disorder that may predispose to seizures or lower seizure threshold * Previously received TP-434 in a clinical trial * More than 24 hours duration of systemic antibiotic coverage for current condition * Received ertapenem or any other carbapenem, or tigecycline for the current infection * Need for concomitant systemic antimicrobial agents other than study drug or received systemic (IV or oral) antibiotics in the last 3 months * Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion or any other resuscitative measures and drug/fluid therapy at time of consent * Known or suspected inflammatory bowel disease or associated visceral abscess